教員情報 - 北中　明

現在の専門分野

著書

学術雑誌

学会発表

所属学会

（最終更新日：2022-02-25 18:21:24）

  キタナカ　アキラ
  北中　明
   所属   川崎医科大学医学部臨床医学　検査診断学（病態解析）

職種教授

■ 現在の専門分野

キーワード：血液腫瘍学、臨床検査医学

■ 著書

1.	2018/11	部分執筆	B　病態・臨床検査（1 一般検査（尿検査，糞便検査，脳脊髄液検査）, 2 血液学的検査, 3 臨床化学検査, 4 免疫学的検査）「薬物治療総論／症候・臨床検査／個別化医療臨床薬学テキストシリーズ」
2.	2018/10	部分執筆	I．造血器腫瘍の新しい分類　1．WHO分類改訂第4版（2017）における骨髄系腫瘍「EBM　血液疾患の治療　2019-2020」
3.	2018/01	部分執筆	骨髄異異形性症候群「今日の治療指針　2018年版」
4.	2021/05	部分執筆	第5章　結果の評価　C　赤血球系疾患　e．赤血球増加症「スタンダード検査血液学」
5.	2020/01	部分執筆	骨髄穿刺法、生検法　（適応と方法）「今日の治療指針 2020年版」
6.	2015/12	部分執筆	骨髄線維症 (MF)「難病辞典」
5件表示
全件表示(6件)

■ 学術雑誌

1.	2019/08	原著	Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
2.	2019/03	原著	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.
3.	2018/07	症例報告	進行する貧血・好中球減少を呈した症例
4.	2018/03	原著	Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents.
5.	2018/02	総説	血液形態診断のためのケースカンファレンス　司会のまとめ（第64回学術集会シンポジウム10）
6.	2018/01	総説	骨髄異形成症候群の診断と病型分類update －2016年改訂WHO分類を踏まえて－
7.	2018/01	原著	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
8.	2017/09	原著	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
9.	2017/05	原著	Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
10.	2017/05	原著	Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
11.	2017/03	原著	TET2 mutation in diffuse large B-cell lymphoma.
12.	2017/03	原著	ルーチン検査(基本的検査)の読み方・考え方　信州大学方式RCPC
13.	2017/03	原著	Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
14.	2017/03	原著	Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
15.	2016/10	総説	CML進行期の対応
16.	2016/09	総説	骨髄異形成/骨髄増殖性腫瘍(分類不能型)の臨床的特徴と治療の選択肢
17.	2016/09	症例報告	骨髄移植後にHHV-6脳炎、髄液内再発をきたしたATLLの一例
18.	2016/05	原著	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
19.	2016/05	原著	All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors.
20.	2016/05	総説	本態性血小板血症の治療　アナグレリドの位置付け
21.	2016/04	原著	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.
22.	2016/09	総説	骨髄異形成/骨髄増殖性腫瘍（分類不能型）の臨床的特徴と治療の選択肢
23.	2016/02	原著	Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
24.	2015/12	原著	Surrounding Gastric Mucosa Findings Facilitate Diagnosis of Gastric Neoplasm as Gastric Adenoma or Early Gastric Cancer.
25.	2015/12	原著	TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
26.	2015/11	症例報告	Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.
27.	2015/11	原著	Integrated molecular analysis of adult T cell leukemia/lymphoma.
28.	2015/09	原著	Analysis of the molecular mechanism underlying bone marrow necrosis with acute lymphoblastic leukemia.
29.	2015/04	原著	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
30.	2015/01	原著	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
31.	2014/12	原著	Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase.
32.	2014/04	原著	Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
33.	2014/03	総説	本邦における原発性骨髄線維症の臨床像
34.	2013/10	総説	骨髄増殖性腫瘍の分子機構と新規薬物療法
35.	2013/06	症例報告	遺伝性球状赤血球症にみられた髄外造血巣
36.	2013/01	原著	Effect of L-thyroxine replacement on apolipoprotein B-48 in overt and subclinical hypothyroid patients.
37.	2012/10	原著	TET2 is essential for survival and hematopoietic stem cell homeostasis.
38.	2012/09	原著	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan.
39.	2012/08	原著	Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation.
40.	2012/06	原著	T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.
41.	2012/03	原著	The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
42.	2012/02	原著	T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.
43.	2011/11	原著	S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13).
44.	2011/10	総説	造血障害とその治療
45.	2011/10	原著	Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.
46.	2011/06	原著	Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR.
47.	2011/02	症例報告	分娩後に発症した後天性血友病の1症例
48.	2010/12	原著	The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation.
49.	2010/10	原著	Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
50.	2010/09	原著	Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation.
51.	2010/06	原著	Immature platelet fraction measurement in patients with chronic liver disease: a convenient marker for evaluating cirrhotic change.
52.	2010/03	原著	Automated assay for determining cellular cholesterol using a random access chemistry analyser.
53.	2010/02	総説	抗凝固物質測定の問題点と標準化に向けての取り組み凝固阻害物質検出のための混合試験の実際と問題点
54.	2010/02	原著	Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
55.	2010/01	原著	Tec protein tyrosine kinase inhibits CD25 expression in human T-lymphocyte.
56.	2009/12	原著	Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.
57.	2009/12	原著	多項目自動血球分析装置XE-2100を用いた幼若血小板比率測定の臨床的有用性　化学療法および造血幹細胞移植後の血小板回復時期の予測マーカーとして
58.	2009/09	原著	Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
59.	2009/06	原著	Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
60.	2009/03	症例報告	Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/(67)gallium scintigraphy abnormality.
61.	2008/02	原著	Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
62.	2006/11	原著	Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells.
63.	2005/04	原著	Cyclosporin A inhibits the early phase of NF-kappaB/RelA activation induced by CD28 costimulatory signaling to reduce the IL-2 expression in human peripheral T cells.
64.	2004/08	原著	Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation.
65.	2004/06	原著	Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
66.	2004/05	原著	Identification of p46 Shc expressed in the nuclei of hepatocytes with high proliferating activity: Study of regenerating rat liver.
67.	2004/03	原著	Analysis of the optimal blood sampling conditions for estimation of hematopoietic progenitor cell count by the SE-9000 automated hematolyzer.
68.	2001/10	原著	Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
69.	2001/10	原著	Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene
70.	2001/09	原著	Growth hormone prevents Fas-induced apoptosis in lymphocytes through modulation of Bcl-2 and caspase-3.
71.	2000/08	原著	Mediation by the protein-tyrosine kinase Tec of signaling between the B cell antigen receptor and Dok-1.
72.	2000/02	総説	CD38 in hematopoiesis.
73.	2000/01	原著	CD38 ligation inhibits normal and leukemic myelopoiesis.
74.	1999/10	原著	Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase.
75.	1999/02	原著	CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain.
76.	1998/02	原著	Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells.
77.	1997/07	原著	CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3-kinase.
78.	1997/04	原著	Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells.
79.	1996/12	総説	Human B-cell progenitors and bone marrow microenvironment.
80.	1996/07	原著	CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-
81.	1996/02	原著	Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
82.	1996/01	原著	CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase.
83.	1994/11	原著	Low-dose continuous subcutaneous infusion of granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in acute myelogenous leukemia and its pharmacokinetics.
84.	1994/06	原著	Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression.
85.	1994/06	原著	Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells.
86.	2022/02	症例報告	Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly
87.	2021/10	原著	Whole-genome landscape of adult T-cell leukemia/lymphoma.
88.	2021/09	原著	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.
89.	2021/05	原著	VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines
90.	2021/03	原著	Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
91.	2020/12	原著	Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma
92.	2020/08	総説	骨髄系腫瘍の臨床　慢性骨髄性白血病　　移行期・急性転化期の慢性骨髄性白血病の病因・病態と治療
93.	2020/07	症例報告	血液形態診断のためのケースカンファレンス　細胞形態の特徴から診断し得た病初期の急性前骨髄球性白血病の1症例
94.	2020/06	原著	パニック値を巡る諸問題と日本臨床検査医学会からの提言　　検体系検査のパニック値を巡る諸問題
95.	2020/02	原著	Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
96.	2020/02	総説	造血器腫瘍のWHO分類改訂第4版(2017年)のポイント　　骨髄系腫瘍
97.	2019/07	症例報告	血液形態診断のためのケースカンファレンス　骨髄標本に赤芽球の増加を認めた汎血球減少症の一例
98.	2018/06	原著	An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS
5件表示
全件表示(98件)

■ 学会発表

1.	2018/11/17	シンポジウム8 血液形態診断のためのケースカンファレンス「骨髄標本に赤芽球の増加を認めた汎血球減少症の一例」（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
2.	2017/11/18	シンポジウム10 血液形態診断のためのケースカンファレンス　「進行する貧血・好中球減少を呈した症例」（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
3.	2017/09/30	アルブミン適正使用の推進：アルブミン製剤一元管理の効果と腹水ろ過濃縮再静注法（CART)の取り組み（口頭発表，一般）
4.	2016/09/04	RCPC2 ルーチン検査(基本的検査)の読み方・考え方―信州大学方式 RCPC― （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
5.	2016/10/13	教育講演18 CML進行期の対応（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
6.	2019/11/24	パニック値を巡る諸問題と日本臨床検査医学会からの提言 1. 検体系検査のパニック値を巡る諸問題（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
7.	2019/11/24	教育講演 4 造血器腫瘍の WHO-2017 分類のポイント造血器腫瘍の WHO 分類改訂第 4 版(2017)のポイント骨髄系腫瘍（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等）
5件表示
全件表示(7件)

■ 所属学会

1.	1991～	日本血液学会
2.	2014～	∟ 評議員
3.	1991～	日本内科学会
4.	2016～	∟ 中国支部評議員
5.	2001～	日本輸血細胞治療学会
6.	2017～	∟ 輸血機能評価認定制度視察員（I&A制度視察員）
7.	2002～	日本臨床検査医学会
8.	2018～	∟ 医療安全委員
9.	2002～	米国血液学会
10.	2007～	日本臨床検査専門医会
11.	2022～	∟ 理事
12.	2016～	日本検査血液学会
5件表示
全件表示(12件)